Asia-pacific Nuclear Medicine Radiopharmaceuticals Market Growth Factors Revealed.
Asia-pacific Nuclear Medicine Radiopharmaceuticals Market Analysis, Size, Share, Growth, Trends, And Forecasts (20162021)
(EMAILWIRE.COM, July 27, 2017 )
According to the report Asia-Pacific Market Nuclear Medicine Radiopharmaceuticals Market, published by Market Data Forecast, the market is estimated at $855 million in 2015 and is expected to reach $1670 million by 2020, growing at a CAGR of 14.3%.
Nuclear medicine falls under the field of Molecular imaging, which involves usage of minute amount of radioactive material (radiopharmaceuticals) to diagnose and treat disease. The market is currently in its growth stage driven by increasing number of cancer cases and rising awareness about nuclear medicine. Radiopharmaceuticals are pharmaceutical formulations comprising radioactive isotopes that are used in diagnosis and therapeutics. They are simple and small substances that contain a radioactive substance that is used in the treatment of cancer and cardiac & neurological disorders.
The conventional chemotherapy methods are being replaced by more convenient therapeutic radiopharmaceuticals for oncology and cancer treatment, which opens up new avenues in the radiopharmaceuticals market. Moreover, it not only helps physicians during diagnosis, but also works as a convenient and safer alternative for patients as compared to X-Rays and other external radiation imaging devices. Radiopharmaceuticals, also known as nuclear medicines, are used in applications such as lymphoma and bone metastasis. F-18, Tc-99, Ga-67, and I-123 are some of the nuclear medicines used in diagnostic procedures, while I-131, Ir-192, Y-90, I-125, Lu-177, and Ra-223 are used in therapeutics procedures.
Get a comprehensive overview of the Nuclear Medicine Radiopharmaceuticals Market: http://www.marketdataforecast.com/market-reports/asia-pacific-nuclear-medicine-radiopharmaceuticals-market-132/
Nuclear Medicine Radiopharmaceuticals Market: Drivers & Restraints
Some of the factors driving the growth of nuclear medicine radiopharmaceuticals market are increasing prevalence of chronic diseases, technological advancements, increasing healthcare expenditure, and increasing demand of radiopharmaceuticals in emerging economies. In addition, rising awareness of radiopharmaceuticals among healthcare providers also fuels growth of the nuclear medicine radiopharmaceuticals market. However, stringent regulatory approvals, high cost of devices using radioisotopes, short half-life of radiopharmaceuticals and availability of conventional diagnostics procedures are some of the factors restraining the growth of the nuclear medicine/radiopharmaceuticals market to some extent.
Get accurate market forecast and analysis on the Nuclear Medicine Radiopharmaceuticals Market. Request a sample to stay up-to-date on the main trends affecting this market: http://www.marketdataforecast.com/market-reports/asia-pacific-nuclear-medicine-radiopharmaceuticals-market-132/request-sample
Nuclear Medicine Radiopharmaceuticals Market: Segmentation
By Type
o Diagnostic Radioisotopes
SPECT
o Technetium-99m
o Thallium-201
o Gallium-67
o Iodine-23
o Others
PET
o Fluorine-18
o Rubidium-82
o Others
o Therapeutic Radioisotopes
Beta Emitters
o Iodine-131
o Yttrium-90
o Samarium-153
o Rhenium-186
o Lutetium-177
Alpha Emitters
o Radium-223
Brachytherapy
o Cesium-131
o Iodine-125
o Palladium-103
o Iridium-192
By Application
o Cardiology
o Lymphoma
o Thyroid
o Neurology
o Oncology
o Others
From simple data collation through secondary and primary research to ad-hoc research requests relating to specific information, we provide our services via customization. Get customization at http://www.marketdataforecast.com/market-reports/asia-pacific-nuclear-medicine-radiopharmaceuticals-market-132/customize-report
Nuclear Medicine Radiopharmaceuticals Market: Overview
Nuclear medicine falls under the field of Molecular imaging, which involves usage of minute amount of radioactive material (radiopharmaceuticals) to diagnose and treat disease. New developments such as Integration of X ray tomography (CT) into SPECT provide an excellent diagnostic tool in medical imaging and are considered to be a driving factor for the growth of the market. Strict regulatory framework poses a potential hurdle to translational research and clinical investigations. Reimbursement issues are also blocking the growth of the market. Convenience of the treatment with minimally invasive techniques attracts more patients towards radiopharmaceuticals mode of treatment as compared to chemotherapy.
Nuclear Medicine Radiopharmaceuticals Market: Region-wise Outlook
The Asia-Pacific region is geographically segmented into China, India, Japan, South Korea, and Australia. Asia Pacific is one of the most lucrative markets for the growth of Nuclear Medicine Radiopharmaceuticals and is projected to grow the highest during the forecast period. Factors such as growing demographics and emerging economies in countries such as India and China are anticipated to lead the growth of the market in this region.
Key Questions Answered
The current and emerging market trends and dynamics in the Asia-pacific nuclear medicine market.
The current market and estimations from 2015 to 2020, which contribute in identifying the key market opportunities for growth.
The Asia-Pacific radiopharmaceuticals market by type helps in understanding the types of radiopharmaceuticals that are currently being used along with the variants that would gain prominence in the future.
Competitive intelligence (of leading manufacturers of radiopharmaceuticals) helps in understanding the competitive scenario across the geographies.
Key market players within the radiopharmaceuticals market are profiled in this report and their strategies are analysed thoroughly. This helps in understanding the competitive outlook of the Asia-Pacific nuclear medicine market.
Nuclear Medicine Radiopharmaceuticals Market: Key Players
Some of the key players influencing the Asia-Pacific nuclear medicine market are GE Healthcare, Hologic Inc., Medix Inc., Segami Corporation, Positron Corporation, Bracco Imaging S.p.A, Naviscan Inc., Bayer Healthcare, Lantheus Medical Imaging, Inc. and IBA Molecular Imaging.
Reasons to buy Nuclear Medicine Radiopharmaceuticals Market Report:
Regional and country-level analysis and forecasts of the study market; providing Insights on the geographical areas in which this industry is prospering
Segment-level analysis on basis of product type, application, colour along with market size forecasts and y-o-y estimations to detect key areas of industry growth in detail
Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
Study of macro and micro environmental factors that affect the market presented in an extensive strategic analyses section containing PESTLE and Porters Five Forces Analyses
A comprehensive listing of key market players along with company overview, product portfolios, key financial information (subjected to availability), SWOT analysis and Analyst overview to study and sustain the market environment
Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
Expertly devised Market Outlook along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
Checkout other related studies in the Pharmaceuticals Segment:
Global Nuclear Medicine Radiopharmaceuticals Market: http://www.marketdataforecast.com/market-reports/global-nuclear-medicine-radiopharmaceuticals-market-130/
Asia-Pacific Anticoccidial drugs: http://www.marketdataforecast.com/market-reports/asia-pacific-anticoccidial-drugs-market-24/
Asia-Pacific Therapeutic vaccines: http://www.marketdataforecast.com/market-reports/asia-pacific-therapeutic-vaccines-market-77/
About Market Data Forecast:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more information, kindly visit, www.marketdataforecast.com.
Contact:
Abhishek Shukla
Sales Manager (International Business Development)
Market Data Forecast
Direct Line: +1-888-702-9626
Mobile: +91 998 555 0206
Mail: abhishek@marketdataforecast.com
Visit Market Data Forecast Blog @ http://www.marketdataforecast.com/blog/
View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases
According to the report Asia-Pacific Market Nuclear Medicine Radiopharmaceuticals Market, published by Market Data Forecast, the market is estimated at $855 million in 2015 and is expected to reach $1670 million by 2020, growing at a CAGR of 14.3%.
Nuclear medicine falls under the field of Molecular imaging, which involves usage of minute amount of radioactive material (radiopharmaceuticals) to diagnose and treat disease. The market is currently in its growth stage driven by increasing number of cancer cases and rising awareness about nuclear medicine. Radiopharmaceuticals are pharmaceutical formulations comprising radioactive isotopes that are used in diagnosis and therapeutics. They are simple and small substances that contain a radioactive substance that is used in the treatment of cancer and cardiac & neurological disorders.
The conventional chemotherapy methods are being replaced by more convenient therapeutic radiopharmaceuticals for oncology and cancer treatment, which opens up new avenues in the radiopharmaceuticals market. Moreover, it not only helps physicians during diagnosis, but also works as a convenient and safer alternative for patients as compared to X-Rays and other external radiation imaging devices. Radiopharmaceuticals, also known as nuclear medicines, are used in applications such as lymphoma and bone metastasis. F-18, Tc-99, Ga-67, and I-123 are some of the nuclear medicines used in diagnostic procedures, while I-131, Ir-192, Y-90, I-125, Lu-177, and Ra-223 are used in therapeutics procedures.
Get a comprehensive overview of the Nuclear Medicine Radiopharmaceuticals Market: http://www.marketdataforecast.com/market-reports/asia-pacific-nuclear-medicine-radiopharmaceuticals-market-132/
Nuclear Medicine Radiopharmaceuticals Market: Drivers & Restraints
Some of the factors driving the growth of nuclear medicine radiopharmaceuticals market are increasing prevalence of chronic diseases, technological advancements, increasing healthcare expenditure, and increasing demand of radiopharmaceuticals in emerging economies. In addition, rising awareness of radiopharmaceuticals among healthcare providers also fuels growth of the nuclear medicine radiopharmaceuticals market. However, stringent regulatory approvals, high cost of devices using radioisotopes, short half-life of radiopharmaceuticals and availability of conventional diagnostics procedures are some of the factors restraining the growth of the nuclear medicine/radiopharmaceuticals market to some extent.
Get accurate market forecast and analysis on the Nuclear Medicine Radiopharmaceuticals Market. Request a sample to stay up-to-date on the main trends affecting this market: http://www.marketdataforecast.com/market-reports/asia-pacific-nuclear-medicine-radiopharmaceuticals-market-132/request-sample
Nuclear Medicine Radiopharmaceuticals Market: Segmentation
By Type
o Diagnostic Radioisotopes
SPECT
o Technetium-99m
o Thallium-201
o Gallium-67
o Iodine-23
o Others
PET
o Fluorine-18
o Rubidium-82
o Others
o Therapeutic Radioisotopes
Beta Emitters
o Iodine-131
o Yttrium-90
o Samarium-153
o Rhenium-186
o Lutetium-177
Alpha Emitters
o Radium-223
Brachytherapy
o Cesium-131
o Iodine-125
o Palladium-103
o Iridium-192
By Application
o Cardiology
o Lymphoma
o Thyroid
o Neurology
o Oncology
o Others
From simple data collation through secondary and primary research to ad-hoc research requests relating to specific information, we provide our services via customization. Get customization at http://www.marketdataforecast.com/market-reports/asia-pacific-nuclear-medicine-radiopharmaceuticals-market-132/customize-report
Nuclear Medicine Radiopharmaceuticals Market: Overview
Nuclear medicine falls under the field of Molecular imaging, which involves usage of minute amount of radioactive material (radiopharmaceuticals) to diagnose and treat disease. New developments such as Integration of X ray tomography (CT) into SPECT provide an excellent diagnostic tool in medical imaging and are considered to be a driving factor for the growth of the market. Strict regulatory framework poses a potential hurdle to translational research and clinical investigations. Reimbursement issues are also blocking the growth of the market. Convenience of the treatment with minimally invasive techniques attracts more patients towards radiopharmaceuticals mode of treatment as compared to chemotherapy.
Nuclear Medicine Radiopharmaceuticals Market: Region-wise Outlook
The Asia-Pacific region is geographically segmented into China, India, Japan, South Korea, and Australia. Asia Pacific is one of the most lucrative markets for the growth of Nuclear Medicine Radiopharmaceuticals and is projected to grow the highest during the forecast period. Factors such as growing demographics and emerging economies in countries such as India and China are anticipated to lead the growth of the market in this region.
Key Questions Answered
The current and emerging market trends and dynamics in the Asia-pacific nuclear medicine market.
The current market and estimations from 2015 to 2020, which contribute in identifying the key market opportunities for growth.
The Asia-Pacific radiopharmaceuticals market by type helps in understanding the types of radiopharmaceuticals that are currently being used along with the variants that would gain prominence in the future.
Competitive intelligence (of leading manufacturers of radiopharmaceuticals) helps in understanding the competitive scenario across the geographies.
Key market players within the radiopharmaceuticals market are profiled in this report and their strategies are analysed thoroughly. This helps in understanding the competitive outlook of the Asia-Pacific nuclear medicine market.
Nuclear Medicine Radiopharmaceuticals Market: Key Players
Some of the key players influencing the Asia-Pacific nuclear medicine market are GE Healthcare, Hologic Inc., Medix Inc., Segami Corporation, Positron Corporation, Bracco Imaging S.p.A, Naviscan Inc., Bayer Healthcare, Lantheus Medical Imaging, Inc. and IBA Molecular Imaging.
Reasons to buy Nuclear Medicine Radiopharmaceuticals Market Report:
Regional and country-level analysis and forecasts of the study market; providing Insights on the geographical areas in which this industry is prospering
Segment-level analysis on basis of product type, application, colour along with market size forecasts and y-o-y estimations to detect key areas of industry growth in detail
Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
Study of macro and micro environmental factors that affect the market presented in an extensive strategic analyses section containing PESTLE and Porters Five Forces Analyses
A comprehensive listing of key market players along with company overview, product portfolios, key financial information (subjected to availability), SWOT analysis and Analyst overview to study and sustain the market environment
Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
Expertly devised Market Outlook along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
Checkout other related studies in the Pharmaceuticals Segment:
Global Nuclear Medicine Radiopharmaceuticals Market: http://www.marketdataforecast.com/market-reports/global-nuclear-medicine-radiopharmaceuticals-market-130/
Asia-Pacific Anticoccidial drugs: http://www.marketdataforecast.com/market-reports/asia-pacific-anticoccidial-drugs-market-24/
Asia-Pacific Therapeutic vaccines: http://www.marketdataforecast.com/market-reports/asia-pacific-therapeutic-vaccines-market-77/
About Market Data Forecast:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more information, kindly visit, www.marketdataforecast.com.
Contact:
Abhishek Shukla
Sales Manager (International Business Development)
Market Data Forecast
Direct Line: +1-888-702-9626
Mobile: +91 998 555 0206
Mail: abhishek@marketdataforecast.com
Visit Market Data Forecast Blog @ http://www.marketdataforecast.com/blog/
View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases
Contact Information:
Market Data Forecast.
Abhishek
Tel: +1-888- 702-9626
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Market Data Forecast.
Abhishek
Tel: +1-888- 702-9626
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results